ArticleBiological psychiatry2021
Activating mGlu
Open access · greenAbstract read
In one paragraph
Article in Biological psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 44 citations in OpenAlex.
- Discovery of VU6052959/BI'7927: A Selective mGluACS medicinal chemistry letters · 2026Article
- Discovery of VU6053371/BI03738809: A First-in-Class Selective and CNS-Penetrant mGluACS chemical neuroscience · 2026Article
- Identifying drug targets for schizophrenia through gene prioritization.Translational psychiatry · 2026Article
- Metabotropic Glutamate Receptor-Dependent Synaptic Plasticity in Age-Related Neurodegenerative Disorders.Neural plasticity · 2026Review
- Post-methamphetamine working memory decline predicts relapse vulnerability in rats and is rescued by mGlu3 receptor activation.Psychopharmacology · 2026Article
- Overexpression of mGluMolecular neurobiology · 2025Article
- A Refined Approach to Isolate Interneurons for High-Validity Epigenetic Studies in Human Brain Tissue.Methods and protocols · 2025Article
- Identification and validation of LY6H and GRM3 as candidate biomarkers for Glioma-related epilepsy.Scientific reports · 2025Article
- Preclinical and clinical study on type 3 metabotropic glutamate receptors in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Plasticity of ventral tegmental area disturbance during abstinence after repeated amphetamine exposure: restoration by selective activation of group II metabotropic glutamate receptors.Frontiers in pharmacology · 2025Article
- Profiling gene alterations in striatonigral neurons associated with incubation of methamphetamine craving by cholera toxin subunit B-based fluorescence-activated cell sorting.Frontiers in cellular neuroscience · 2025Article
- Pharmacological Blockade of Group II Metabotropic Glutamate Receptors Reduces the Incidence of Brain Tumors Induced by Prenatal Exposure to N-ethyl-N-nitrosourea in Rats.Current neuropharmacology · 2025Article
- Evolutionary and functional analysis of metabotropic glutamate receptors in lampreys.Fish physiology and biochemistry · 2024Article
- Activation of Metabotropic Glutamate Receptor 3 Modulates Thalamo-accumbal Transmission and Rescues Schizophrenia-Like Physiological and Behavioral Deficits.Biological psychiatry · 2024Article
- Emerging modes of regulation of neuromodulatory G protein-coupled receptors.Trends in neurosciences · 2024Review
- Article
- Group I and group II metabotropic glutamate receptors are upregulated in the synapses of infant rats prenatally exposed to valproic acid.Psychopharmacology · 2023Article
- Neurotransmitters in Prevention and Treatment of Alzheimer's Disease.International journal of molecular sciences · 2023Review
- mGlu3 Metabotropic Glutamate Receptors as a Target for the Treatment of Absence Epilepsy: Preclinical and Human Genetics Data.Current neuropharmacology · 2023Article
- Transcriptome analysis reveals genes associated with stem cell activation by physical exercise in the dentate gyrus of aged p16Ink4a knockout mice.Frontiers in cell and developmental biology · 2023Article
Corrections and comments
- Commented on bymGlu2021
Authors and funding
10 authors at 3 institutions in 2 countries.
Shalini DograDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee.
Branden J StansleyDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee.
Zixiu XiangDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee.
Weilun QianVanderbilt University, Nashville, Tennessee.
Rocco G GogliottiMolecular Pharmacology and Neuroscience Department, Loyola University Chicago, Maywood, Illinois.
Ferdinando NicolettiIRCCS Neuromed, Pozzilli, Italy; Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee; Vanderbilt Center for Addiction Research, Vanderbilt University, Nashville, Tennessee.
Colleen M NiswenderDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee; Vanderbilt Kennedy Center, Vanderbilt University, Nashville, Tennessee.
Max E JoffeDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee; Vanderbilt Center for Addiction Research, Vanderbilt University, Nashville, Tennessee. Electronic address: max.joffe@vanderbilt.edu.
P Jeffrey ConnDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee; Vanderbilt Center for Addiction Research, Vanderbilt University, Nashville, Tennessee; Vanderbilt Kennedy Center, Vanderbilt University, Nashville, Tennessee. Electronic address: jeff.conn@vanderbilt.edu.
Vanderbilt University · USIstituto Neurologico Mediterraneo · ITLoyola University Chicago · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MREGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9MOverall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3MFUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPESR01NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 1993 to 2025
$6.2MFunctions of Metabotropic Glutamate Receptor SubtypesR37NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2014 to 2020
$3.5MA precision medicine approach to Rett SyndromeR01NS112171 · NINDS · LOYOLA UNIVERSITY CHICAGO · PI GOGLIOTTI, ROCCO GEORGE · 2020 to 2024
$1.7MNormalizing E:I imbalance in Rett Syndrome by Modulation of Late Response GenesK01MH112983 · NIMH · VANDERBILT UNIVERSITY · PI GOGLIOTTI, ROCCO GEORGE · 2017 to 2020
$543kSex differences in fast-spiking interneurons promote AUD-related PFC dysfunction: remediation by modulating mGlu1 and mGlu5K99AA027806 · NIAAA · VANDERBILT UNIVERSITY · PI JOFFE, MAX E · 2020 to 2021
$276kNCI NIH HHS P30 CA068485NEI NIH HHS P30 EY008126NIAAA NIH HHS K99 AA027806NICHD NIH HHS P50 HD103537NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIMH NIH HHS F32 MH111124NIMH NIH HHS K01 MH112983NIMH NIH HHS R01 MH062646NINDS NIH HHS R01 NS031373NINDS NIH HHS R01 NS112171NINDS NIH HHS R37 NS031373
Abstract
backgroundPolymorphisms in GRM3, the gene encoding the mGlu
methodsWe examined associative learning in mice with trace fear conditioning, a hippocampal-dependent learning task disrupted in patients with schizophrenia. Underlying cellular mechanisms were assessed using ex vivo hippocampal slice preparations with selective pharmacological tools and selective genetic deletion of mGlu
resultsmGlu
conclusionsThese data demonstrate that activation of mGlu
Indexed as
Receptors, Metabotropic GlutamateSchizophreniaAnimalsCognitionHippocampusLong-Term PotentiationMicemetabotropic glutamate receptor 3Receptors, Metabotropic GlutamateCognitionHippocampusmGlu(3)mGlu(5)SchizophreniaSynaptic plasticity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.